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Introduction 
 When a human infant is born prematurely, they are unable to receive the adequate 
nutrient and mineral requirements from parenteral or enteral sources that would have been 
provided to them in most intrauterine states. Preterm infants have low birth weights as the 
majority of fetal weight gain occurs in the third trimester. Term infants can also be growth 
restricted at birth for reasons pertaining to placental challenges such as pregnancy induced 
hypertension, arterial venous anastomosis as in to twin transfusion syndrome, or when severe 
maternal malnutrition exist. While not necessarily preterm, the products of these gestations will 
need similar nutritional supplementation for growth and healthy neurodevelopment as the 
preterm infant. The goal of many neonatal advanced practice nurse providers is to maintain 
growth rates similar to the uterine environment and often times in the face of critical illnesses or 
challenges. When adequate nutrition is not administered, extra-uterine growth restriction occurs. 
Growth restriction has been directly correlated to the decreased structure and function of the 
central nervous system, specifically when the restriction is during critical periods development 
such as the neonate period. The central nervous system deficits are irreversible (Ziegler, 2011).  
Growth goals that have been established for the preterm neonatal period is a weight gain of 15 
g/kg/day, occipital frontal circumference growth of 0.5cm/week and length increases of 1 
cm/week (Georgieff, 2005). The ability for a preterm infant to grow and have similar organ 
development at intrauterine rates requires they receive increased amounts of protein, fat, and 
minerals when compared to newborn term infants. To establish these goals, daily protein intake 
should be 3.4-4.2gm/kg/day and caloric intake of 110-135kcal/kg/day, with the degree of 
prematurity directly indicating nutritional needs on the higher side (Arslanoglu, Moro, & Ziegler, 
2010). In addition to monitoring weekly measurements of preterm infants, serum lab work can be 
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useful as indicators for growth and used to guide fortification of feedings. Serum sodium, 
chloride, calcium and phosphorus requirements are necessary to monitor as the premature infant 
will quickly develop defects following umbilical cord clamping exacerbated by their immature 
kidney functioning. Trends in prealbumin, BUNs, and alkaline phosphate levels are also used as 
indicators of protein status and markers of bone health respectively. Extra-uterine growth 
restriction has a direct correlation to neurodevelopment challenges and is therefore an area of 
importance to providers caring for these vulnerable infants. Excluding parenteral nutrition, the 
ways in which neonatal care units provide growth restricted  infants these requirements are by 
enteral administration via a naso/orogastric tube of own mother’s breast milk (OMM), donor 
breast milk (DBM), and preterm formulas (PF).   
Human Milk 
 The literature supports improved neurodevelopment, cardiovascular health, and decreased 
risks of cancer and other infectious incidences when infants are breastfed or provided OMM 
(Gomella, 2009 and Arslanoglu, 2010). The properties of human milk (HM) that make it superior 
for immunologic protection and developmental benefits include live cells, enzymes, and immune 
factors (Georgieff, 2005).  In addition to immunologic properties, HM is higher in fat than PF, a 
benefit for premature infants, but low in protein and sodium which are both essential for the 
somatic growth of premature infants. Pumped HM is also considered an inexpensive option for 
families and health care systems. 
 OMM produced from mothers of preterm infants and term infants differs in its nutritional 
qualities. The mother of an infant delivered preterm produces milk that has a higher content of 
protein, chloride and sodium for the first 1-2 weeks, up to the first month postpartum. This richer 
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preterm HM is a natural fortification for the underdeveloped neonate (Zeigler, 2011 & Gross, 
David, Bauman, & Tomarelli, 1980).  
Donor milk 
Multiple sources state the majority of breast milk donated to milk banks is from mothers 
of term infants (Lindemann, Foshauge, & Lindemann 2004); therefore, the widely accepted 
assumption is the protein content is not adequate to sustain or grow a preterm infant as it is from 
term mothers. While OMM has a variable amount of protein content regardless of the mother’s 
gestiation, DM is “less variable, but lower in protein content” than any OMM (Zeigler, 2011). In 
addition to the differences of preterm milk and term milk, protein content also decreases 
throughout the course of lactation (Arslanoglu, Moro, & Ziegler, 2010), therefore donors who’s 
own infants are now four or five months old will produce a less nutrient rich milk. DM also 
undergoes a process OMM does not which is a pasteurization process, most often Holder 
pasteurization. Holder pasteurization is the heating of milk to 62.5 degrees Celsius for 30 
minutes. DM is then cultured and frozen to -20 degrees Celsius before being dispensed (Human 
Milk Banking of North America, 2011). Human milk oligosaccharides and long-chained 
polyunsaturated fatty acids are two immune factors that are maintained in DM throughout Holder 
Pasteurization process (Bertino et al., 2008). Human milk oligosaccharides work with the 
immune system and are responsible for prebiotic functioning and protection of intestinal 
infections and long-chained polyunsaturated fatty acids assist with immunological protection of 
the gastrointestinal track (Arslanoglu, Ziegler, & Moro, 2010). While these factors are 
maintained, fractions of many immunologic factors such as sIgA, IgA, lactoferrin, lysozyme, 
lymphocyte, lipase, and alkaline phosphatase are lost in the intense heating process. While not 
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utilized as frequently and less studied, a shorter pasteurization process exists which is heating to 
72 degrees Celsius five times, each time for 15 seconds (Heiman & Schanler, 2006).    
 Processes are in place and regulated in an attempt to ensure the safety of DM. Donors of 
milk are routinely tested for cytomegalovirus, HIV, and Hepatitis B and C before donating and 
throughout the process to confer safety for the already immuno-suppressed preterm infant who 
will receive the DM. The possibility for viral transmission exists even if the donor serum is 
negative at the time of donation. Finally, the process of pasteurization presents possible bacterial 
contamination of DM, therefore all samples are cultured for colonization prior to distribution 
(Lindemann, Foshaugen, & Lindeman, 2003).  
Fortification 
 All HM, OMM or DM, is inadequate in the amounts of nutrients for the premature infant. 
Standard practice is to fortify HM with human milk fortifier (HMF) when enteral feedings have 
been advanced to 100ml/kg/day. HMFs, currently extracted from cow’s milk, contain protein, 
carbohydrates, fats, and essential vitamins and minerals which afford providers the ability to 
keep volumes of feedings in a range of 150-160ml/kg/day (Zeigler, 2011). Current research is 
ongoing for the development of an HMF from human milk called Prolacta.   
Gut Maturation and Necrotizing Enterocolitis 
 Preterm infants are not born with mature intestinal tracks, necessitating the need for slow 
advancements in enteral feedings along with the use of total parenteral nutrition. Throughout the 
history of neonatology, feedings were withheld and advanced slowly as the risk of necrotizing 
enterocolitis (NEC) was realized (Zeigler, 2011). NEC is an inflammatory process of the bowel 
in response to an intolerance of a substrate in the bowel lumen for reasons still unknown to 
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providers. The bowel wall becomes damaged and, in severe stages, perforates leaking intestinal 
contents into the peritoneum, a life threatening event. The field of neonatology now agrees the 
way to mature the gut, increase motility, and promote microbial properties is to provide small 
amounts of HM, OMM or DM consistently for the first few days to a week to prime the intestinal 
track. These small feedings, called trophic feedings, are not utilized by the baby as essential 
nutrition and parenteral nutrition continues to be utilized for administration of protein, fats, and 
essential minerals. The immunologic properties of fresh OMM are absorbed by the infant’s 
mucosal track which is called passive immunity, something pasteurized milk is less able to do 
secondary to decreased amounts of IgA. Benefits of trophic feedings with OMM are two-fold, 
intestinal maturity and immunologic protection.    
 DM is widely used by neonatal care units when OMM is unavailable and before PF is 
considered as the risk of NEC is higher for premature infants receiving PF. Infant receiving DM 
who are born on the edge of viability will receive DM for up to 6-8 weeks before they are 
switched to PF around 32 to 34 weeks postmenstral age.  This makes them vulnerable to the 
negative neurodevelopment effects of extra-uterine growth restriction. The increasing usage of 
DM necessitates an in-depth understanding regarding the benefits and consequences of its use. A 
literature search on the subject of DM for optimal growth of preterm infants was surprising as 
current research on the topic was limited. This lack of substantiated evidence in the literature 
suggests the side effects of DM many not be fully realized by providers and necessitates the need 
for further studies. 
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Literature Review 
 In a randomized control trial published in 2005, Schanler et al. compared infants under 30 
weeks gestation receiving exclusively OMM and infants who were supplemented with DBM or 
PF when OMM was not available.  A wide variety of short term outcome data were analyzed 
including length of stay (LOS), infectious rates, including NEC, growth rates, and rates of skin to 
skin contact between the mother and infant. To clarify, all subjects received some amount of 
OMM, which was a limitation of this study because it is not clear how much OMM the subjects 
received before being supplemented. The results could be confounded as the protective benefits 
of OMM hid some outcome effects of the supplementation; however, the authors do point out the 
amount of OMM received was not statistically different between the DM and PF groups. When 
the control group, exclusive OMM, was compared to the DM and PF groups, infection rates were 
improved, including decreased incidences of NEC, fewer gram negative cultures, shorter LOS, 
and less severe staging of ROP rates, supporting common opinion that OMM is best for 
premature infants. Another important factor the authors point out is the similar characteristics of 
the subjects’ mothers who provided enough OMM. They were older, had a higher SES, and 
visited their infant more, perhaps a confounding variable of the health of their infant regardless 
of the supplementation use for enteral feedings. When DM was compared to PF there were no 
differences in outcomes of NEC, LOS, or death. Slower weight gain was noted in the DM group. 
This difference was so drastic, the principle investigator along with the attending neonatologists 
switched 17 infants from the DM group to the PF before the end of the study. No difference in 
OFC occurred throughout the three groups, however both DM and PF groups lagged behind 
OMM group for length. It was also noticed that DM group needed higher sodium 
supplementations and both the DM and PF groups needed higher oil or protein supplements 
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when compared to the control OMM group.  In the study design, the authors point out Enfamil 
Human Milk Fortifier and Similac Human Milk fortifiers (likely the hospital contract changed 
mid-study) are added to the OMM and the DM when the infants reached 100ml/kg/day of 
feeding volume. The PF used was Enfamil Premature Formula, also specialized for premature 
requirements. The DM was pumped from mothers of premature infants. This is an interesting 
difference as most studies on DM do not specify the characteristics of the mother donating. Some 
milk banks do keep DM pumped from mothers of preterm infants separate and sell it to hospitals 
as preterm DM. This only seems to legitimize the results of this study further. Perhaps making 
this a more thorough study would be inclusion of serum markers of growth between the two 
groups. 
 In a prospective observational study of infants born under 32 weeks gestation, researchers 
compared the growth of infants fed <20% OMM, more than 80% OMM, and those fed 20-80% 
OMM with the supplementation being DM. Standard fortification was used for both OMM and 
DM when feedings reached 100ml/kg/day. Using statistical significance values of p <0.05, 
results indicated a mean weight gain of 5.1g/kg/day lower for infants fed less than 20% OMM.  
Infants receiving 20-80% OMM had growth rates of 4.8g/kg/day lower and those fed >80% 
OMM reached growth rates similar to intrauterine amounts of 15gm/kg/day. While this was a 
small, single hospital study, without randomization and minimal controls, it does show results 
consistent with other studies. The conclusion was properties of DM were insufficient to grow 
premature infants at intrauterine rates (Montjauz-Régis, Cristini, Glorieux, Vanpee, and Casper, 
2010).  
 A meta-analysis of seven studies, five of which were randomized control trials, were 
reviewed to compare the use of OMM, pasteurized DM, and PF for outcomes of death, NEC, 
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infection and growth for premature and growth restricted infants. True meta-analysis was not 
possible as the outcome variables for growth were not standardized across the studies. For the 
trials evaluating growth, it was concluded that there was a tendency for improved early postnatal 
weight gain, increased OFCs, and skin fold thickness, but no gains in length for those fed 
formula. Three of the studies evaluated the risk of NEC and concluded presumed cases of NEC 
were not statistically significant; yet, confirmed rates of NEC were statistically lower for subjects 
fed DM compared to PF. A combined risk difference of the 3 studies was determined to be 5.4%, 
meaning 18.5 premature infants would need to be given donor milk instead of formula to prevent 
one case of NEC. While this is a recent review, the studies were published in the 1970s and 
1980s which is problematic as the field of knowledge for nutrition in neonatology has improved 
since that time. The studies that evaluated DM did not include DM that was fortified with HMF, 
a practice now standard.  Thus interpretation of results must be done carefully when comparing 
unfortified DM to PF. Another important factor to consider is the variable outcome criteria for 
the studies used, making analysis difficult (Boyd, Quigley, & Brocklehurst, 2007).   
 A Cochrane database review compared DM to PF to evaluate growth of premature infants 
and low birth weight infants, born less than 37 weeks gestation and weighing less than 2.5kg at 
birth respectively. Studies included eight randomized controlled trials, including Schanler, et al. 
from 2005 as outlined previously in this paper. Schanler et al. remains the only study to date 
comparing fortified DM to formula, the others use unfortified DM.  Schanler et al. is also the 
only study within the last decade, all others included in this analysis were from the 1970 and 
1980s. This meta-analysis concluded short term growth rates were higher for those fed formula 
verses DM. Long term outcome data was analyzed and failed to show a difference in growth 
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rates or neurodevelopment outcome. This analysis indicated the incidence of NEC is statistically 
increased in those fed formula over DM (Quigley, Henderson, Anthony, & McGuire, 2008).  
Implications 
 The trials frequently cited in the literature, excluding one, are considered dated material 
in modern neonatology, specifically with the changes in nutrient goals for premature infants. 
Proponents of DM may argue that growth rates and development will not matter if the infant 
suffers mortality secondary to NEC and therefore argue that OMM and DM are the only suitable 
options for premature infants. However, as stated in the meta-analysis by Boyd and colleagues, 
18.5 infants will need to receive DM to save one from death due to NEC.  This risk-benefit can 
be a difficult for providers to weigh. Rather, the practice should perhaps be to give all infants 
OMM or DM through the first 14 days of life or first 14 days of feedings, when NEC is most 
likely to occur and then switch to PF to focus energies on growth and development of the infant. 
This increases the number of infants exposed to DM, something some parents may not feel 
comfortable with and choose to withhold consent.  Again, these conclusions are based on studies 
that, for the most part, are decades old. It is clear more randomized control trials need to take 
place before widespread recommendations are given. Currently, multiple neonatal intensive care 
units are shifting towards increased usage and longer duration of DM feedings when OMM is not 
available. In addition to the increased cost on the already stressed healthcare system, it is 
puzzling since the literature review suggests it may not be the liquid silver (OMM being the 
liquid gold) some believe it to be. Other options for the continued use of DM for this population 
would be to target fortification individually; meaning all milk is tested for its protein, fat and 
energy content and fortification is specialized to the individual neonate. Currently, serum 
markers of protein status such as BUN, albumin and prealbumin are evaluated and a standard 
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assumption of the qualities of DM is used. Again, this is a labor intensive activity and likely a 
further expense on an already taxed system. If perfection remains what providers strive for, this 
is the next modification.   
 Feeding low birth weight premature infants is a challenging task for the neonatal nurse 
practitioners responsible for guiding the care of such infants.  Forming a partnership with parents 
is vital for open communication and education surrounding this topic.  Honest communication 
with families regarding feedings and the possible morbidities that threaten preterm infants is 
essential. Advance practice nurses have the potential to encourage and support maternal pumping 
of milk.  Some situations can preclude the amount of OMM available, regardless of maternal 
intent to provide, including maternal illness, medications, or breast tissue damage and must be 
approached with support, sensitivity and care and without judgment. This is a challenging task, 
but one neonatal nurse practitioners are capable of. It is essential all families are given all the 
information regarding feeding their premature infants so they are able to make informed 
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